Institut Rosell — Company Profile

Lallemand SAS 19, rue des Briquetiers BP 59 31702 Blagnac Cedex France Tel.: +33 (0)5 62 74 55 55 Fax: +33 (0)5 62 74 55 00 Email: human@lallemand.com Website: http://www.institut-rosell.com/

Institut Rosell is the Human Health and Nutrition Division of the Canadian-based Lallemand Group. A pioneer in probiotic applications since 1934, Institut Rosell's mission is to study, develop and produce probiotic solutions to help maintain and restore people's health and well-being.

Today, Institut Rosell concentrates its research efforts on the scientific and clinical documentation of its probiotics strains and formulations developed for their health benefits, including gastrointestinal, the immune system, women's health and children's health. Thanks to branch offices in Europe, North America and Asia, these products are distributed worldwide, either under Institut Rosell's own trademark, or via major players within the food supplement and pharmaceutical industries focused on consumer healthcare.


Source: Institut Rosell

[Read more!]

Seppic — Company Profile

SEPPIC SA Tour Kupka C 7, boulevard Franck Kupka 92039 Paris - La Défense Cedex France Tel.: +33 (0)1 55 91 57 00 Fax: +33 (0)1 55 91 50 50 Email: info.seppic@airliquide.com Website: http://www.seppic.com/

SEPPIC currently has over 600 staff world-wide. Together, they are creating, developing and promoting innovative speciality chemical and biological products designed to meet the requirements of a wide range of markets including cosmetics, human health, animal health, nutrition, textiles, paper, fertilisers, lubricants, drilling, detergents, optical cables, glass, building, resins, plastics and polymers, paints and inks. SEPPIC offers its customers a wide range of high performance and innovative products.

SEPPIC is a company based within the international Air Liquide group. The state of the art ressources of Air Liquide allow SEPPIC to create the products needed in tomorrow's markets.

SEPPIC has widely recognised international expertise dedicated to ensuring customer satisfaction offering made-to-measure services, with the aim of Total Quality, to meet the economic challenges of the 21st century.

R&D, Marketing

Research lies at the heart of our company. We have brought our Research, Development and Marketing departments together so that our research and development is in touch with market trends.

This enables us to offer tools and services able to meet rapidly changing requirements.

Control over the design, the application and the use of our speciality chemical and biological products are essential for developing our markets.

The Castres Research Centre places its science and services at the service of customers to develop products for the future.

Over 80 research workers apply their expertise to synthesising chemical and biological products and improving the performance of our speciality chemicals, in particular for the beauty, medicine, health and hygiene markets as well as special applications for glass, lubricants, plastics and polymers, paper and textiles.

SEPPIC's research is also based on collaboration with public and private research organisations such as CNRS, INRA, INSERM and AFSSA. These joint research projects enable SEPPIC to respond more accurately and more quickly to meet the market requirements for technical performances.

Quality

The quality of products and services, environment, health and safety issues have been central to SEPPIC's strategy since 1989.

Its Total Quality objective is based on continual staff training and staff motivation and has clearly defined aims: respect for its customers, the environment and its staff and compliance with regulations.

Quality: always aiming to improve customer satisfaction while listening to them.

SEPPIC is certified to ISO 9001 to ensure control over all aspects from safety to use of its products. The "processus" management according to V 2000 is underway.

— Quality policy and specific improvement objectives
— Co-operation with suppliers, sub contractors and customers
— Improving the reliability of processes and production equipment
— Continual improvement of manufacturing practices

Health and Safety: objective "zero accidents"

— Procedures, audits, objectives and annual reports
— Motivation, training and preventive education
— Daily safety training
— Control over products used and the risks they represent
— Appropriate work methods and means of protection

Environment: protection of our natural environment

The environment is of major concern to SEPPIC:

— ISO 14001 certification mid 2000
— Control and reduction of liquid waste and pollutant gases
— Studies of waste and waste treatment
— Studies of risks and prevention of technological risks
— Product life cycle environmental accounting

Improvement of good manufacturing and responsible care practises is a permanent concern.


Other locations in France:

SEPPIC has two production subsidiaries in France and a new subsidiary in Antwerp, Belgium.
Each has its own range of speciality chemicals with production management systems controlling quality, productivity and total traceability.
As part of the Total Quality policy, Good Manufacturing Procedures are gradually being introduced in the various units.

SEPIPROD Castres
127, chemin de la Poudrerie
81108 Castres
France
Tel.: +33 (0)5 63 72 69 69
Fax: +33 (0)5 63 72 69 70

This unit covers an area of 8 hectares and manufactures 600 different products with an annual output of 30,000 tonnes. Castres produces mainly surfactants and surfactant-based products (sorbitan esters, alkylpolyglucosides, amides, betaines, etc.).

Additional products include, for example, polymers, pharmaceutical and veterinary excipients as well as glass frosting materials and special products for optical fibre cables.


Givaudan-Lavirotte
56, rue Paul Cazeneuve
BP 8344
Lyon 08
France
Tel.: +33 (0)4 78 61 55 00
Fax: +33 (0)4 78 61 55 94

The Givaudan-Lavirotte unit makes pharmaceutical and nutritional products and also provides services to the cosmetics industry. Its products are mainly used as ingredients for health products (mineral salts, nicotinates and undecylenates, protein surfactant complexes, etc.).


Source: Seppic

[Read more!]

Pierre Fabre Castres - Peraudel — Company Profile

Institut de Recherche Pierre Fabre 17, Avenue Jean Moulin 81106 Castres Cedex France Tel.: +33 (0)5 63 71 42 00 Fax: +33 (0)5 63 35 66 29 Website: http://www.pierre-fabre.com/

Medical chemistry (central nervous system, cardio-vascular diseases).

Sector of activity
Research & Development

Branch of activity
Pharmacy

Personnel
232 Persons


Source: Pierre Fabre

[Read more!]

Pierre Fabre Ramonville - Ariane — Company Profile

Institut de Recherche Pierre Fabre Parc Technologique du Canal 3, rue Ariane 31527 Ramonville Cedex France Tel.: +33 (0)5 61 73 73 00 Fax: +33 (0)5 61 73 73 73 Website: http://www.pierre-fabre.com/

Innovation Development Center Pierre Fabre.

Sector of activity
Research & Development

Branch of activity
Pharmacy

Personnel
142 Persons


Source: Pierre Fabre

[Read more!]

MidiMed — Company Profile

MidiMed ZI du Bousquet 31360 Boussens France Tel.: +33 (0)5 61 97 69 69 Fax: +33 (0)5 61 87 17 59 Website: http://www.midimed.com/

MidiMed manufactures reagents for cell culture. We are committed to provide quality products and services to research laboratories and industrialists according to their needs.

• Standard and innovative culture media,
• Additives and antibiotics,
• Sera, albumins, plasma of most species and origins,
• Immunoglobulins,
• An innovative serum free range of products, "SafeCell".

MidiMed was created in July 2004; our 2000 m² factory located in Boussens, south of Toulouse offers you:

• Standard and customized Culture media.
• Serum Free media, based on containing vegetable extracts.
• Serums and plasma of most species and origins.
• Capacity to produce lots above 1000 litres.
• Additives and antibiotics for cell culture.
• Albumins and immunoglobulins.

The MidiMed company invested in several research projects in order to replace animal proteins by plant proteins.


Source: MidiMed

[Read more!]

Genibio — Company Profile

Genibio Voie Haussmann ZI du Couserans 09190 Lorp-Sentaraille France Tel.: +33 (0)5 61 04 80 18 Fax: +33 (0)5 61 04 80 38 Website: http://www.genibio.eu/

Founded in the late 1990s, GENIBIO develops innovative and natural ingredients such as probiotics, protein hydrolysates and vegetal extracts for the food supplement, pharmaceutical and cosmetic markets.

• From science to industry: GENIBIO is present all along the innovation chain and proposes an integrated approach from research and validation of active compounds and extracts to the production of the final ingredient.
• With high quality standards: Since 2004, a quality policy with an approach based on GMP (Good Manufacturing Practices) and HACCP (Hazard Analysis Critical Control Point) has been established.
• A partnership strategy: GENIBIO develops strong partnerships, with industrial groups and academic research units. Located in the South-West of France, GENIBIO benefits from the proximity of Toulouse, one of the key French scientific centers in the field of health and biotechnology.

With a high dedicated skills panel and a powerful technological platform, GENIBIO is now the right partner for innovation from research to production of natural ingredients, used in health, health foods and cosmetics markets.


History

With the initial aim of developing research-based innovation for the market of food and cosmetic ingredients, GENIBIO was focused on R & D strong partnerships in the field of services.

1998: Creation of GENIBIO in Toulouse by François Paul, after a rich and diversified professional course in industrial and academic worlds.
With the initial aim of developing research-based innovation for the market of food and cosmetic ingredients, GENIBIO was focused on R & D strong partnerships in the field of services.

1999: Creation of GENIBIO INDUSTRIE.
Located in Lorp-Sentaraille and created to manufacture the ingredients issued from GENIBIO research, GENIBIO INDUSTRIE started up with the production of plant protein hydrolysates by enzyme technology.

Since 2002: GENIBIO research team settled in the same place as GENIBIO INDUSTRIE.
Now, GENIBIO is fully operational in its industrial site and offers a complete service from research to production of vegetal ingredients and probiotics.


Organisation

Currently, the site of GENIBIO employs about 30 persons, with one third of the people involved in R&D activities and distinguishes by its diverse and young team with expertise in biocatalysis, microbiology, extraction techniques, production processes, analytical methods and quality assurance.

GENIBIO R & D provides services for the development of innovative ingredients: natural plant extracts and probiotics.

Staff 10 persons
Facilities:

• Laboratory of Microbiology: selection and objectivation of lactic acid bacteria and bifidobacteria, development of probiotics and synbiotics formulae
• Laboratory of Biochemistry: development of extraction techniques and analytical methods

GENIBIO INDUSTRIE offers infrastructures for plant extraction and enzymatic hydrolysis processes.

Staff 20 persons
Industrial facilities: 2,000 m²
GENIBIO premises include a main production area for the manufacturing of fine powders (protein hydrolysates and other plant extracts), an alcoholic plant extraction platform, a control quality laboratory and two separated warehouses for raw materials and finished products.


Key Facts

Skills and Know-how:

• Research & Development and Production of natural ingredients
• Dedicated skills in Microbiology, Biocatalysis, Extraction technology, separation and filtration techniques

Core business areas:

• Probiotics, prebiotics and synbiotics: PRIMAFLOR^®
• Herbal and seaweed extracts
• Soy germ extracts and fermented soy germ: PRIMASOY^®
• Enzymatic protein hydrolysates and peptides: HYPRO^®

Markets:

• Food supplements
• Natural cosmetic ingredients
• Health, notably PAP (Pharmaceutical Active Principles) for phytotherapy

Source: Genibio

[Read more!]

BT Pharma — Company Profile

BT Pharma Headquarters and Laboratories Prologue-Biotech Rue Pierre et Marie Curie BP 28262 31682 Labège-Innopole Cedex France Tel.: +33 (0)5 61 28 70 60 Fax: +33 (0)5 61 28 70 69 Email: business@btpharma.com Website: http://www.btpharma.com/

BT PHARMA is an emerging biopharmaceutical company focused on developing innovative therapeutic vaccines caused by human papillomavirus (HPV) for the treatment of cervical cancer and associated neoplasia. The company's lead candidate therapeutic vaccine, ProCervix^® is scheduled to receive approval for its first clinical trials in 2009. BT PHARMA plans to develop ProCervix^® to proof of concept stage.

The company was created in October 2001 and is based in Labège (Toulouse), France.

Corporate Profile

BT PHARMA is an emerging biopharmaceutical company focused on developing innovative therapeutic vaccines for the treatment of cervical cancer and associated neoplasia.

Cervical cancer and associated neoplasia are a major healthcare problem. They are the result of infection by the Human Papillomavirus (HPV) and are one of the most common sexually transmitted diseases affecting women.

BT PHARMA’s lead candidate therapeutic vaccine, ProCervix^® is scheduled to receive approval for its first clinical trials in 2009. ProCervix^® is based on BT PHARMA’s unique CyaA vector system which is able to deliver the appropriate HPV antigens needed to induce strong and specific T cell responses. BT PHARMA plans to develop ProCervix^® to proof of concept stage. The company then intends to work with an appropriate partner to further develop and commercialize this exciting new therapeutic vaccine product.

In addition, BT PHARMA has a number of other therapeutic vaccine development programs based on its CyaA vector system. These are TAAVAC, for Tumour Associated Antigen Vaccine for a range of human cancers, and DOGTAA, which targets many cancers in companion animals.

Finally, the company also has a second vaccine vector called PepTel^® which uniquely has intrinsic adjuvant ability. This promising technology platform is available for licensing.

BT PHARMA is managed by a team of experienced biotech professionals and has developed a strong network of collaborators. The company continues to work with scientists, at Institut Pasteur, who are the world leading experts in the CyaA vector technology. The company also works with leading clinicians with significant experience in conducting clinical trials with cervical cancer vaccines.

BT PHARMA started operations in October 2001 following its spin off from the Institut Pasteur. The company is headquartered in state-of-the-art facilities in Labège (Toulouse), France and employs 18 people.

Source: BT Pharma

[Read more!]

Orfagen — Company Profile

Orfagen Parc Technologique du Canal 4, rue Marie Curie BP 22132 31521 Ramonville Saint Agne Cedex France Tel.: +33 (0)5 62 24 76 83 Fax: +33 (0)5 61 24 76 86 Website: http://www.orfagen.com/

A pharmaceutical company dedicaded to dermatological rare disorders.
Subsidiary company of the Pierre Fabre Laboratories, ORFAGEN develops new drugs for patients affected by rare diseases with dermatological impact.


Orfagen is a new pharmaceutical laboratory, working with the best dermatologists in the field towards an objective of creating new drugs and medicines from research to market place.

Profile

Orfagen develops pharmaceutical and biotechnology products to treat patients suffering from skin disorders, and is particularly interested in the innovation of treatments for rare and serious skin conditions where treatment has not, as yet, been provided. Orfagen will also make available more conventional treatments that are insufficiently dispensed and reimbursed to patients.

with the Pierre Fabre Laboratories, whose interests and expertise in dermatology is world renowned, as the main shareholder. Orfagen’s current research portfolio has thus been carried out without the need for supplementary outside funding.

Key Points

• The Pierre-Fabre Group as major shareholder, highly dedicated to dermatology
• Assured long-term funding
• Advanced research portfolio
• Worldwide expertise in dermatology

Strategy

Resulting from the use of an original technique for the identification of new molecules and drug discovery (Capture-Recapture Search and Validation technique, CARES-V), Orfagen’s current portfolio includes seven research projects. Product sources are products developed in-house, in-licensed products and products developed in cooperation with outside partners. Orfagen’s partners are either large international pharmaceutical companies, which cannot devote resources or focus on orphan products, or biotechnology companies seeking a co-development and/or commercial partner in Europe. Universities and public research institutes also participate with Orfagen in the development of certain projects.

For its commercial activities, Orfagen will implement its own marketing resources and sales forces throughout the European Union. Promotion of Orfagen’s products will be mainly directed towards university hospitals and specialised centres. Orfagen can also take advantage of the worldwide commercial structure of Pierre-Fabre, which is represented in more than 100 countries.

Human Resources

Orfagen currently employs staff covering activities in clinical drug development, regulatory affairs and administration. The marketing and commercial structures will be implemented in the near future.

Achievements

Four projects in Orfagen's portfolio have already reached their clinical development phase. The company owns five orphan drug designations granted by the European Agency for Medicinal Products (EMEA), and two designations by the US Food and Drug Administration (FDA). Acquisition of value is also built on exclusive licensing rights in some projects.

Fields of Interest

• Dermatology
• Rare disorders
• Dermatological diseases with unresolved medical needs
• Innovative therapies and projects
• Biotechnologies

Source: Orfagen

[Read more!]

Pierre Fabre Labège I — Company Profile

Centre de Développement Pierre Fabre (CDPF) Rue Jean Rostand BP 687 31319 Labège-Innopole Cedex France Tel.: +33 (0)5 62 24 27 00 Fax: +33 (0)5 61 39 96 50 Website: http://www.pierre-fabre.com/

Invent a new galenic, ensure the development of new actives, validate pre-clinical and clinical drug dossiers.

Brands
Pierre Fabre Medicament

Sector of activity
Research & Development

Branch of activity
Pharmacy


Source: Pierre Fabre

[Read more!]

Pierre Fabre Gaillac — Company Profile

Plantes & Industrie ZA des Clergous 16, rue Jean Rostand 81603 Gaillac Cedex France Tel.: +33 (0)5 63 81 24 00 Fax: +33 (0)5 63 57 32 07 Website: http://www.pierre-fabre.com/ Website: http://www.plantes-industrie.com/

Plant extracts, pure actives, neutraceutics. Actives produced through hemisynthesis or total synthesis. FDA approval.

Brands
Pierre Fabre Medicament

Sector of activity
Research & Development

Branch of activity
Pharmacy

Personnel
329 persons


Source: Pierre Fabre

[Read more!]

LibraGen — Company Profile

LibraGen Bâtiment Canal Biotech 1 3, rue des Satellites 31400 Toulouse France Tel.: +33 (0)5 62 19 32 90 Fax: +33 (0)5 61 73 27 56 E-mail: contact@libragen.com Website: http://www.libragen.com/

Building on bacterial diversity, we discover, develop and improve innovative bioprocesses for the industrial production of healthcare molecules.

Corporate Overview

Summary
LibraGen uses innovative and proprietary functional genomic technologies in combination with industrial expertises to develop new bioprocesses for the discovery of novel bioactives and the improvement of production processes of added value molecules.
Libragen's competitive edge is embodied by its ability to turn the huge genetic and chemical diversity of the 99% of bacteria that can not be cultured under conventional conditions into an accessible reservoir of biomolecules. These biomolecules are an unlimited bioresource for the development of active pharmaceuticals, agrochemicals and food ingredients as well as intermediates and bulk chemicals. Mastering the whole process from the discovery to the industrialisation, LibraGen reinforces its client's competitiveness and market share.

Mission
LibraGen aims at becoming a leader in the discovery and development of bacterial diversity-deriver processes for the industrial production of molecules that concerns the red (healthcare) as well as the white (industry) sectors of modern biotechnology. LibraGen masters the whole process, from lab-based discovery to industrialization. To maximise the industrial application of the research and development activity, LibraGen includes the industrial constraints of the used of bioprocesses for large scale production at early stage in the definition of the research strategy. The company intends to rapidly meet the needs of businesses due to increasing pressure on production costs and therefore the needs for innovation. LibraGen considers that this is a major business opportunity one which is likely to generate significant added value.

LibraGen main features
LibraGen's resources cover all aspects of biocatalysis, namely new biocatalyst discovery by taking advantage of its metagenomic technology as well as selection of accessible enzymes and cultivable microbes, molecular evolution, substrate choice and supply or substrate synthesis using classical chemistry, target or bioassay oriented screening of biomolecules, biotransformation medium engineering, product recovery, purification, characterisation and identification.
LibraGen starts with functionnal genomics (genes and biosynthetic pathways) by taking advantage of its metagenomic platform to end at the establishment of the optimised production protocols with the production of sample amounts. LibraGen combines in-house projects and fully integrated projects within the framework of contract research and development agreements (full services and out-sourcing), R&D partnership and alliances. In house projects, in collaboration with wellknown european academic partners, allow all the company to build up continuously its resources and to keep abreast of the latest technological advances in molecular biology, chemistry as well as in the biocatalysis and fermentation fields. With a strong know-how in molecular biology, fermentation, biotransformation reactions, extraction and purification of biomolecules, its commitment to custom-made, cost-effective and confidential collaborations, LibraGen carries out tailor-made multitechnology R&D projects in a reliable manner as far as the technical and management aspects are concerned.

• Incorporated in February 2001 and located in Toulouse (France).
• Highly skilled scientific and managerial employers.
• 500 sq. m of equiped lab with the state-of-the art techniques in Microbiology, Molecular Biology and Chemistry.
• Strategic combination of expertises optimized with an important European academic network.
• Bioprocessing pilot plant available in an integrated capabilities, From discovery to Kilolab technology platform.
• Exclusive technologies.

Facilities
New Active Molecules and Biocatalysts discovery from untapped bacterial diversity.

• Molecular High Through-put Screening.
• Primary screening for the discovery of anti-infectious and anti-tumoral compounds.
• Molecular Evolution.

Chemistry unit for natural product purification and characterisation and organic synthesis

• Up/Down stream processes improvement (optimization in fermentation and biocatalysis)
• Scale-up transfer to the industrial partner.

Source: LibraGen

[Read more!]

IEB (Institut Européen de Biologie Cellulaire) — Company Profile

Institut Européen de Biologie Cellulaire 18, avenue de l'Europe 31520 Ramonville St Agne (Toulouse) France Tel.: +33 (0)5 62 88 73 00 Fax: +33 (0)5 62 88 73 01 Website: http://www.ieb.fr/

Created in 1993, the Institut Européen de Biologie cellulaire brought together scientists from the pharmaceutical industry. The research teams have developed and produced innovative biomimetic oligopeptides used by the largest cosmetic companies.

The assessed performances of our ingredients have given the I.E.B. the opportunity to register six international patents and to be awarded two trophies.

Our research team has developed and perfected an innovative concept of actives in dermo-cosmetology.

Our peptidic actives stimulate and strengthen the different skin functions. They also make up for physiopathological disorders linked to skin ageing and stress thanks to their regenerative capacities.

Spread through the skin, our biocompatible products have a perfectly determined action on the various elements making up the skin, without any systemic effect.



Source: Institut Européen de Biologie Cellulaire

Editor's Note: The IEB is part of the Unipex Group since May 2008.

[Read more!]

GTP Technology — Company Profile

GTP Technology Bâtiment Biostep Rue Pierre et Marie Curie — BP 48184 31681 Labège Cedex France Tel.: +33 (0)5 61 28 70 20 Fax: + 33 (0)5 61 28 70 21 Email: contact@gtptech.com Website: http://www.gtptech.com/

GTP Technology is a contract research organization providing tailor-made solutions for recombinant proteins expression and engineering.

Our services target pharmaceutical and cosmetic industry, biotech companies, food industry and academic laboratories, for numerous applications: high throughput screening, preclinical studies, functional and structural analysis...

GTP Technology is a biotech company dedicated to provide tailor-made solutions for the engineering and expression of recombinant proteins. The company was set up in 2000 by Eric Devic (Pharm.D. PhD) as a spin out from the Protein Engineering Department of P. Sabatier University in Toulouse, France.

GTP Technology offers its customers a comprehensive set of services for recombinant proteins, from gene cloning to protein production and purification and also, now, structural analysis with the Eiffel Biostructure platform. In addition, the company has extended its range of services and offers Real-Time PCR protocols development or optimization.

GTP Technology is renowned for its expertise — more than 200 proteins produced up to now — and for the quality of its services. As a result, the company has become one of the privileged partners of the main French pharmaceutical, biotech and food companies.

GTP Technology is located in Labege (near Toulouse), France.


Source: GTP Technology

[Read more!]